臺灣博碩士論文加值系統

過去，「授權學名藥」（Authorized Generic, AG）被視為專利藥廠削減學名藥挑戰專利意願、阻止first-filer進入市場的武器，但近年來，專利藥廠與學名藥廠的合作時有所聞，專利藥廠與學名藥廠之間的授權實例逐漸增加，專利藥廠與學名藥廠的競合變得更加多元。「授權學名藥」應可成為學名藥廠在自行以逆向工程研發藥品以外的另外一種策略選擇。
然而，台灣製藥產業中的授權學名藥並不常見，因此在以學名藥廠觀點出發的相關研究中，尚未有充分的解釋，或很少被檢視。本研究之目的，在於探討學名藥廠在何種條件下可選擇與專利藥廠策略結盟，選擇上市「授權學名藥」，並且運用設計結構矩陣（Design Structure Matrix, DSM）來改善評估流程。
本研究經整理歸納文獻後，提出可行性決策假說模型，將開發標的藥品依照技術可行性與市場可行性分類為四個象限。第一象限之藥品可視原廠品牌力效果高低，選擇「授權學名藥」策略或自行開發；第二象限之藥品應選擇「授權學名藥」策略；第三象限之藥品不予開發；第四象限的藥品則選擇自行開發。
公司在使用模型決策前，須先進行可行性評估工作。評估工作的流程順序繁雜，可先使用設計結構矩陣分析來進行流程精簡與改善後再執行。經過評估，公司可得知開發標的藥品在可行性決策模型上的最終落點，進而做出最終決策。期待此假說模型及運用DSM改善流程的方式能作為學名藥廠的未來參考，建議未來相關研究能補足此假說模型之不足，並精進流程管理上Domain Mapping Matrix （DMM）與Multi Domain Matrix（MDM）的相關應用。

In the past, “Authorized Generic” (AG) was regarded as a weapon for innovator companies to reduce the willingness of generic drug companies to challenge patents and prevent first-filers from entering the market. However, in recent years, more and more cooperation between brand-name and generics manufacturers were announced, and the number of authorized licensing projects between innovator companies and generic drug companies has gradually increased, it means the competition and cooperation between innovator companies and generic drug companies have become more diverse. "Authorized generic drugs" should be taken into consideration as another strategic choice for generic drug companies to develop drugs other than self-development.
In the pharmaceutical industry in Taiwan, authorized generic drugs are not common. Therefore, the related studies from the viewpoint of generic drug manufacturers have not been sufficiently explained or even reviewed. The purpose of this study is to explore the conditions under which generic drug companies can choose to strategically form alliances with innovator companies to market "authorized generic drugs", and to recommend the use of Design Structure Matrix (DSM) to improve the evaluation process.
After reviewing and summarizing the literature, this study proposes a feasibility decision-making hypothesis model, and classifies the development target drugs into four quadrants according to technical feasibility and market feasibility. For drugs in quadrant I, after weighing the brand power effect of the originators, generic drug companies can choose between the strategy of "authorized generic drugs" and self-development; for drugs in the quadrant II, companies should select the strategy of "authorized generic drugs"; for drugs in the quadrant III, they shall not be developed; and for drugs quadrant IV, companies shall choose to develop on their own.
Before the company uses the model to make decisions, it must first conduct a feasibility assessment. Since the process of the assessment is complicated, the company can use DSM analysis to improve the process flow before execution. After the assessment, the company obtains the positioning of the target drug to develop on the feasibility decision model plot, and then make the optimal decision.
It is hoped that this hypothetical model and the application of DSM to improve the process flow can be regarded as a future reference for generic drug companies. It is recommended that future related studies can complement the deficiencies of this hypothetical model, and extend the applications of Domain Mapping Matrix (DMM) and Multi Domain Matrix (MDM) in process management.

誌謝 I
中文摘要 II
ABSTRACT III
CONTENTS目錄 V
圖目錄 VII
表目錄 VIII
CHAPTER 1 緒論 1
1.1 問題背景 1
1.2 研究目的 4
1.3 研究方法 5
1.4 論文結構 6
CHAPTER 2 文獻回顧 7
2.1 學名藥產業的重要性 7
2.2 台灣學名藥產業面臨的困難 12
2.3 現有流程改善方法－設計結構矩陣之介紹 17
2.3.1 活動型矩陣 20
2.3.2 改善耦合區塊的流程 22
2.3.3 活動型矩陣的優點與限制 22
2.4 DOMAIN MAPPING MATRIX與MULTIPLE DOMAIN MATRIX 24
CHAPTER 3 建構學名藥廠選擇策略之評估流程與模型 27
3.1 可行性決策模型 27
3.1.1 技術可行性 27
3.1.2 市場可行性 27
3.1.3 決策模型 28
3.2 運用DSM改善可行性評估流程 30
CHAPTER 4 結論 40
4.1 DSM改善流程之成果 40
4.2 專家會議驗證 42
4.3 結論 43
參考書目 44

[1]2002產業競爭力-專利商品化之挑戰. Retrieved from https://pcm.tipo.gov.tw/PCM2010/PCM/02_publish/publish_compete1.aspx
[2]2018醫藥產業年鑑. (2018). (許毓真 Ed.): 財團法人生物技術開發中心.
[3]2020醫藥產業年鑑. (2020). (許毓真 Ed.): 財團法人生物技術開發中心.
[4]Browning, T., Fricke, E., & Negele, H. (2006). Key Concepts in Modeling Product Development Processes. Systems Engineering, 9, 104-128. doi:10.1002/sys.20047
[5]Browning, T. R. (2001). Applying the design structure matrix to system decomposition and integration problems: A review and new directions. Ieee Transactions on Engineering Management, 48(3), 292-306. doi:Doi 10.1109/17.946528
[6]Browning, T. R., & Technology and Policy Program. (1998). Modeling and analyzing cost, schedule, and performance in complex system product development.
[7]Chandon, P. (2004). Case Section — Innovative marketing strategies after patent expiry: The case of GSK's antibiotic Clamoxyl in France. Journal of Medical Marketing, 4(1), 65-73. doi:10.1057/palgrave.jmm.5040144
[8]Daiichi Sankyo's Espha Starts Generics Sales Operations. (2010). Retrieved from https://medtech.pharmaintelligence.informa.com/SC073239/Daiichi-Sankyos-Espha-Starts-Generics-Sales-Operations
[9]Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha. (2017, February 15). Retrieved from https://www.daiichisankyo.com/media/press_release/detail/index_3378.html
[10]Danilovic, M., & Browning, T. R. (2007). Managing complex product development projects with design structure matrices and domain mapping matrices. International Journal of Project Management, 25(3), 300-314. doi:10.1016/j.ijproman.2006.11.003
[11]The Design Structure Matrix (DSM). Retrieved from https://dsmweb.org/
[12]Dusetzina, S. B., Keating, N. L., & Huskamp, H. A. (2021). Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access. Jama Internal Medicine. doi:10.1001/jamainternmed.2020.8450
[13]Eppinger, S. D. (1993). A model-based method for organizing tasks in product development. Retrieved from https://EconPapers.repec.org/RePEc:mit:sloanp:2468
[14]Eppinger, S. D., & Browning, T. R. (2016). Design structure matrix methods and applications: Cambridge, Massachusetts : The MIT Press.
[15]FDA List of Authorized Generic Drugs. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/fda-list-authorized-generic-drugs
[16]Gaudilliere, J. P. (2008). How pharmaceuticals became patentable: the production and appropriation of drugs in the twentieth century. History and Technology, 24(2), 99-106. doi:10.1080/07341510701810906
[17]Generic Drugs Market Size Worth Around US$ 675.2 Bn by 2030. (2021, February 10). Retrieved from https://www.globenewswire.com/news-release/2021/02/10/2173401/0/en/Generic-Drugs-Market-Size-Worth-Around-US-675-2-Bn-by-2030.html
[18]Global Branded Generics Market. (2020, July 20). Retrieved from https://www.pharmiweb.com/press-release/2020-07-20/branded-generics-market-is-accounted-for-us-4440-million-at-a-73-cagr-by-2027-finds-coherent
[19]Greene, J. A. (2014). Generic : the unbranding of modern medicine. Baltimore: Johns Hopkins University Press.
[20]Hatch-Waxman Letters. (07/19/2018). Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters
[21]Larson, N., & Kusiak, A. (1996). Managing design processes: A risk assessment approach. Ieee Transactions on Systems Man and Cybernetics Part a-Systems and Humans, 26(6), 749-759. doi:Doi 10.1109/3468.541335
[22]Pfizer Completes Transaction To Combine Its UPJOHN Business With Mylan. (2020, November 16). Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business
[23]Sagonowsky, E. (2018, April 3). The top 15 drug patent expirations of 2018. Retrieved from https://www.fiercepharma.com/special-report/top-10-patent-expirations-2018
[24]Sagonowsky, E. (2021, March 9). The top 10 drugs losing U.S. exclusivity in 2021. Retrieved from https://www.fiercepharma.com/special-report/top-10-drugs-losing-u-s-exclusivity-2021
[25]The Sandoz Brand. (2003). Retrieved from https://www.sandoz.com/about-us/who-we-are/sandoz-brand
[26]Staton, T. (2010). Sanofi, Nichi-iko announce Japanese joint venture. Retrieved from https://www.fiercepharma.com/sales-and-marketing/sanofi-nichi-iko-announce-japanese-joint-venture
[27]Steward, D. V. (1981). The Design Structure-System - a Method for Managing the Design of Complex-Systems. Ieee Transactions on Engineering Management, 28(3), 71-74. doi:Doi 10.1109/Tem.1981.6448589
[28]Takeda and Teva Establish "Teva Takeda Yakuhin Ltd." in Japan. (2016, April 1). Retrieved from https://www.takeda.com/newsroom/newsreleases/2016/takeda-and-teva-establish-teva-takeda-yakuhin-ltd.-in-japan/
[29]藥品查驗登記審查準則, (2010).
[30]杜蕙蓉. (2021). 併購發威 保瑞拚營收翻倍. Retrieved from https://ctee.com.tw/news/biotech/408897.html
[31]林宏文. (2019). 勇闖國際市場 美時如何五年脫胎換骨？. 今周刊, 1158. Retrieved from https://www.businesstoday.com.tw/article/category/80408/post/201902260019/%E5%8B%87%E9%97%96%E5%9C%8B%E9%9A%9B%E5%B8%82%E5%A0%B4%20%20%E7%BE%8E%E6%99%82%E5%A6%82%E4%BD%95%E4%BA%94%E5%B9%B4%E8%84%AB%E8%83%8E%E6%8F%9B%E9%AA%A8%EF%BC%9F
[32]邱柏綱. (2017, July 29). 產值降進口增 藥廠面臨困境. Retrieved from https://www.chinatimes.com/newspapers/20170729000136-260210?chdtv
[33]翁啟惠. (2007). 生技製藥產業在台灣的發展. Retrieved from 總統府月會專題報告:
[34]陳琮淵, & 王振寰. (2009). 台灣的生技製藥產業：發展、創新與限制. 臺灣社會學刊(43), 159-208.
[35]彭梓涵. (2019, June 6). 2018製藥研發預算Top10 半數大藥廠研發經費下降. Retrieved from https://www.gbimonthly.com/2019/06/47187/
[36]經濟部生技醫藥產業發展推動小組. (2020). 2020生技產業白皮書. Retrieved from https://www.biopharm.org.tw/images/2020/Biotechnology-Industry-in-Taiwan-2020.pdf
[37]読めばわかる！オーソライズド　ジェネリック（AG). Retrieved from https://www.daiichisankyo-ep.co.jp/ag/
[38]衛生福利部. (2015). 全面完成藥廠符合PIC/S GMP，並積極推動藥品「源頭」與「運銷」管理. Retrieved from https://www.mohw.gov.tw/cp-2642-20865-1.html
[39]衛生福利部中央健康保險署. (2014). 新制健保藥價調整改革上路. Retrieved from https://www.nhi.gov.tw/News_Content.aspx?n=FC05EB85BD57C709&sms=587F1A3D9A03E2AD&s=1B03BA6DD08418DE
[40]鄭景玲. (2019). 製藥工程師報到-技職新亮點、製藥大躍進. Retrieved from https://rndc.ntut.edu.tw/p/404-1037-97738.php?Lang=zh-tw
[41]篠原, 拓. (2019). オーソライズド・ジェネリックの拡大－後発薬市場の活性化は進むか? Retrieved from https://www.nli-research.co.jp/report/detail/id=61569?pno=2&site=nli
[42]醫藥產業年鑑2017. (2017). (許毓真 Ed.): 財團法人生物技術開發中心.